



## Breakout 4

### Delivering health impact at scale

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health, GSK

Dr Thomas Breuer, Chief Global Health Officer, GSK

Interactive event for investors and analysts. This webinar is being recorded.

# Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for the full year (FY) 2022 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in the Q1 2023 earnings release and Annual Report on Form 20-F for FY 2022.

All guidance, outlooks, ambitions and expectations should be read together with the Guidance, assumptions and cautionary statements in GSK's Q1 2023 earnings release and the 2022 Annual Report.

Basis of preparation: GSK satisfied the formal criteria according to IFRS 5 for treating Consumer Healthcare as a 'Discontinued operation' effective from 30 June 2022. On 18 July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. Comparative figures have been restated on a consistent basis. Earnings per share, Adjusted earnings per share and Dividends per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022.

# Speakers



**Deborah  
Waterhouse**  
CEO, ViiV Healthcare and  
President, Global Health,  
GSK



**Dr Thomas Breuer**  
Chief Global  
Health Officer, GSK

# Changing the trajectory of infectious diseases that disproportionately affect the underserved in lower-income countries

GSK's ambition is to positively impact the health of at least **2.5 billion** people over the next **ten years**, including **1.3 billion** people in **low-income countries**

- Targeted R&D
- Responsible pricing
- Access and equity strategies
- Partnerships



Reaching people  
at scale every  
day


## Immunisation



>1bn

vaccine doses supplied to Gavi\*

## NTD elimination



11bn+

tablets of albendazole donated to  
eliminate Lymphatic Filariasis

## Broadening access



21m (>80%)

people living with HIV in LMICs  
have access to generic  
formulations of our medicines

\* Since 2010 (HPV, Rotavirus, Pneumococcal Vaccines)

# Doing well by doing good, creating value for patients and GSK

- ASO1 adjuvant
- FDA priority review vouchers
- Patent extensions
- Increased efficiencies through scale
- Building trust to attract the best people and partners



## Spotlight: HIV

The greatest barrier to treating and preventing HIV is access to and uptake of affordable medicines

- >80% on DTG based regimen
- Providing access to innovative long-acting injectable for prevention
- 50% of children on HIV treatment take a generic version of dispersible dolutegravir.



## Spotlight: Malaria

A child dies of malaria every minute in sub-Saharan Africa, the region that bears the overwhelming burden of the disease

- First and only *P. falciparum* malaria vaccine for children
- Radical cure for *P. Vivax* malaria in adults



## Spotlight: Tuberculosis

TB should be **preventable** and **curable** yet it is the second **leading infectious killer** after COVID-19

- Vaccines innovation: First candidate TB vaccine in 100 years
- Changing the treatment paradigm in TB



# Recognition of our impact

## #1 in the Access to Medicines Index

Our commitment to improving our global health impact has been recognised by:

- The **Access to Medicine Index**, where we have ranked number one in all 8 waves since its inception in 2008.
- Our people, who tell us they are proud to work for GSK through our employee engagement survey

2022 ACCESS TO MEDICINE INDEX – OVERALL RANKING






# Q & A

# Getting ahead of infectious diseases with GSK management

Four Q&A-focused, virtual breakout sessions




## Seasonal respiratory viruses

Session 1: 14:30-15:00 BST  
Session 2: 15:15-15:45 BST

Phil Dormitzer  
Christi Kelsey  
Luke Miels

IR: [jeffrey.r.mclaughlin@gsk.com](mailto:jeffrey.r.mclaughlin@gsk.com)




## Bacterial and fungal infections

Session 1: 14:30-15:00 BST  
Session 2: 15:15-15:45 BST

Kumaran Vadivelu  
Rob Bowers  
David Redfern

IR: [joshua.x.williams@gsk.com](mailto:joshua.x.williams@gsk.com)



## Chronic viral infections

Session 1: 14:30-15:00 BST  
Session 2: 15:15-15:45 BST

Chris Corsico  
Lizzie Champion  
James Greenhalgh  
Tony Wood

IR: [mick.j.readey@gsk.com](mailto:mick.j.readey@gsk.com)



## Delivering health impact at scale

Session 1: 14:30-15:00 BST  
Session 2: 15:15-15:45 BST

Deborah Waterhouse  
Thomas Breuer

IR: [frances.p.defranco@gsk.com](mailto:frances.p.defranco@gsk.com)